Pieris Pharmaceuticals Email Format

Biotechnology ResearchMassachusetts, United States11-50 Employees

In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, forming a clinical-stage biopharmaceutical company focused on therapies for serious, rare genetic skin diseases that lack FDA-approved options. The company operates within the biotechnology research sector and is based in Boston, Massachusetts. Its development strategy centers on the QTORIN platform, with candidates such as QTORIN rapamycin gel and QTORIN pitavastatin aimed at dermatologic and vascular malformation conditions. 

The patient population includes individuals affected by microcystic lymphatic malformations, cutaneous venous malformations, angiokeratomas, and disseminated superficial actinic porokeratosis. In 2026, Palvella disclosed development updates for its QTORIN rapamycin gel and QTORIN pitavastatin programs, reflecting a broader focus on a QTORIN-based pipeline for serious skin diseases and vascular malformations.

Get verified Pieris Pharmaceuticals emails free

Company overview Employee directory